Reply
- PMID: 26990665
- PMCID: PMC5082702
- DOI: 10.1002/acr.22878
Reply
Comment on
-
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.Arthritis Care Res (Hoboken). 2016 Feb;68(2):151-66. doi: 10.1002/acr.22708. Epub 2015 Sep 24. Arthritis Care Res (Hoboken). 2016. PMID: 26401907 Free PMC article.
-
Treatment of Patients with Nonradiographic Axial Spondyloarthritis Who Have Negative Magnetic Resonance Imaging Results and Normal C-Reactive Protein Levels at Baseline: Comment on the Article by Ward et al.Arthritis Care Res (Hoboken). 2016 Jun;68(6):886. doi: 10.1002/acr.22877. Arthritis Care Res (Hoboken). 2016. PMID: 26990588 No abstract available.
References
-
- Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94. - PubMed
-
- Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–86. - PubMed
-
- Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:2091–102. - PubMed
-
- Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebocontrolled Phase 3 study. Ann RheumDis. 2014;73:39–47. - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
